Download Files:
LPM4870108
SKU
HY-132229-Get quote
Category Reference compound
Tags Cancer, Neuronal Signaling;Protein Tyrosine Kinase/RTK, Trk Receptor
Products Details
Product Description
– LPM4870108 is a potent and orally active pan-Trk (WT and MT) inhibitor, with IC50s of 0.2 nM, 2.4 nM, 3.5 nM and 2.3 nM for TrkC, TrkA, TrkAG595R and TrkAG667C, respectively. LPM4870108 shows selectivity for Trk over ALK (IC50=182 nM). LPM4870108 exhibits anti-tumor activity[1][2].
Web ID
– HY-132229
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C20H19FN6O3
References
– [1]Liu Z, et, al. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer. J Med Chem. 2021 Jul 22;64(14):10286-10296.|[2]Duan S, et, al. Assessment of the toxicity and toxicokinetics of the novel potent tropomyosin receptor kinase (Trk) inhibitor LPM4870108 in rhesus monkeys. Regul Toxicol Pharmacol. 2021 Jun;122:104886.
CAS Number
– 2803679-07-2
Molecular Weight
– 410.40
SMILES
– O=C1C2=C3N(C=CC(N4[C@@H](C5=CC(F)=CN=C5OCC6(N1)CC6)COCC4)=N3)N=C2
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Trk Receptor
Isoform
– TrkA;TrkC
Pathway
– Neuronal Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.